CareDx, Inc (NASDAQ:CDNA) Stake Increased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 59.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 327,343 shares of the company's stock after buying an additional 122,356 shares during the period. Allspring Global Investments Holdings LLC owned about 0.61% of CareDx worth $7,008,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CDNA. Quarry LP purchased a new stake in shares of CareDx in the 3rd quarter valued at approximately $27,000. Royce & Associates LP boosted its holdings in shares of CareDx by 0.3% in the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company's stock valued at $12,280,000 after buying an additional 1,000 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of CareDx by 37.8% in the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company's stock valued at $175,000 after buying an additional 1,540 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in shares of CareDx in the 3rd quarter valued at $52,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of CareDx by 6.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 29,107 shares of the company's stock valued at $623,000 after buying an additional 1,816 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. StockNews.com cut shares of CareDx from a "buy" rating to a "hold" rating in a report on Tuesday. HC Wainwright restated a "neutral" rating and issued a $26.00 target price on shares of CareDx in a report on Tuesday, January 14th. BTIG Research lowered their target price on shares of CareDx from $40.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, November 5th. Finally, Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and decreased their price target for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $28.33.

Insider Buying and Selling

In other CareDx news, Director Peter Maag sold 5,000 shares of CareDx stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the director now directly owns 330,024 shares of the company's stock, valued at $8,250,600. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.90% of the company's stock.

CareDx Stock Down 4.7 %

Shares of CDNA traded down $1.09 during mid-day trading on Friday, hitting $22.29. The company had a trading volume of 898,901 shares, compared to its average volume of 858,255. The business's 50-day simple moving average is $22.69 and its 200-day simple moving average is $25.40. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84. The stock has a market cap of $1.20 billion, a PE ratio of -8.26 and a beta of 1.87.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.